NEW YORK, NY / ACCESS Newswire / May 7, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=147399&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 7, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=147397&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / WHY: New York, N.Y., May 7, 2025.

Gold declined below the $3400 level amid profit-taking.

Omnicell, Inc., a small cap medical technology solutions provider, posted its Q1 results Tuesday. Both top and the bottom-line results beat the consensus. However, thanks to some new headlines and reduced forward guidance, OMCL shares sold off 15% in trading yesterday. A buying opportunity? An analysis around Omnicell follows in the paragraphs below.

AMZN remains cheap near 10Y P/E lows, as the worst of the tariff war headwinds are likely priced in through the management's softer FQ2'25 guidance. We believe that the company remains well positioned to weather the near-term uncertainties, thanks to its growing AWS/ Prime subscription/ advertising opportunities. These reasons are also why we believe that AMZN's intensified capex has been directly top/ bottom-line accretive, as observed in the leading cloud market share and growing multi-year RPOs.

American Financial's Q1 results reflect lower property and casualty insurance underwriting profit and lower returns from the alternative investment portfolio.

PHG's first-quarter results reflect a decline in sales and earnings due to weaker demand in China, leading to lowered 2025 guidance and a cautious outlook.

The Investment Committee debate the fall in Google searches on Apple devices and what it means for both companies. CNBC's Steve Kovach joins us with the latest.

Ceragon Networks Ltd. (NASDAQ:CRNT ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Rob Fink – Head-Investor Relations Doron Arazi – Chief Executive Officer Ronen Stein – Chief Financial Officer Conference Call Participants Christian Schwab – Craig-Hallum Scott Searle – ROTH Capital Ryan Koontz – Needham Theodore O'Neil – Hills Research Operator Ladies and gentlemen, thank you for standing by and welcome to Ceragon Networks' Earnings Call.

With a 26% YTD rise, NatWest's strong performance outperformed US banks and aligns with European peers, reflecting resilience amid market volatility. The bank's robust financials include a 2.27% net interest margin, a 13.8% CET1 ratio, and a projected 16% return on equity. Strategic moves like reducing government stake, acquiring Metro Bank assets, and collaborating with OpenAI enhance NatWest's growth and operational efficiency.

NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / WHY: New York, N.Y., May 7, 2025.

Improved segmental performances benefit VRSK's top line in the first quarter of 2025.

With DAL stock gaining recently, we assess its investment worthiness at current levels.

Advanced Micro Devices' Q1 2025 results reflect robust Client and Data Center revenues, offsetting weakness in the Gaming and Embedded segments.

Howmet (HWM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Maplebear (CART) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Frontdoor (FTDR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

TFS Financial (TFSL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.